MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$416,572K
Issuance of common stock
under equity-based...
$1,088K
Net cash provided by
(used in) investing...
$179,989K
Net cash provided by
financing activities
$1,088K
Canceled cashflow
$236,583K
Net decrease in cash
and cash...
$5,327K
Canceled cashflow
$175,750K
Purchase of marketable
securities
$236,534K
Purchase of property and
equipment
$49K
Equity-based compensation
expense
$36,040K
Accrued expenses and
other liabilities
$8,026K
Prepaid expenses and
other current assets
-$6,897K
Depreciation and
amortization
$311K
Net cash used in
operating activities
-$175,750K
Canceled cashflow
$51,274K
Net loss
-$219,879K
Accretion on marketable
securities
-$6,306K
Accounts payable
-$839K
Back
Back
Cash Flow
source: myfinsight.com
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)